| scholarly article | Q13442814 |
| P2093 | author name string | A Gazit | |
| A Levitzki | |||
| G Blum | |||
| P433 | issue | 51 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 15705-12 | |
| P577 | publication date | 2000-12-26 | |
| P1433 | published in | Biochemistry | Q764876 |
| P1476 | title | Substrate competitive inhibitors of IGF-1 receptor kinase | |
| P478 | volume | 39 |
| Q34065882 | A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition |
| Q34552164 | A homogeneous, high-throughput assay for phosphatidylinositol 5-phosphate 4-kinase with a novel, rapid substrate preparation |
| Q33672991 | Adaptive potentiation in rod photoreceptors after light exposure |
| Q40211075 | Advances towards the development of ATP-competitive small-molecule inhibitors of the insulin-like growth factor receptor (IGF-IR). |
| Q40579821 | Ca(2+) calmodulin kinase and calcineurin mediate IGF-1-induced skeletal muscle dihydropyridine receptor alpha(1S) transcription |
| Q39553440 | Cannabinoid CB1 receptors transactivate multiple receptor tyrosine kinases and regulate serine/threonine kinases to activate ERK in neuronal cells. |
| Q40142014 | Comparison of three approaches for inhibiting insulin-like growth factor I receptor and their effects on NSCLC cell lines in vitro |
| Q37335142 | Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer |
| Q27639414 | Crystal structure of the Apo, unactivated insulin-like growth factor-1 receptor kinase. Implication for inhibitor specificity |
| Q30812778 | Development of new insulin-like growth factor-1 receptor kinase inhibitors using catechol mimics |
| Q58860086 | Discovery of 4-Benzylamino-Substituted α-Carbolines as a Novel Class of Receptor Tyrosine Kinase Inhibitors |
| Q28488169 | Dual targeting of insulin and venus kinase Receptors of Schistosoma mansoni for novel anti-schistosome therapy |
| Q36519010 | Dysregulation of growth factor signaling in human hepatocellular carcinoma. |
| Q34192237 | Dystroglycan modulates the ability of insulin‐like growth factor‐1 to promote oligodendrocyte differentiation |
| Q28077347 | FAM83 proteins: Fostering new interactions to drive oncogenic signaling and therapeutic resistance |
| Q36939898 | Flying under the radar: the new wave of BCR-ABL inhibitors |
| Q35551142 | Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor |
| Q34319607 | Identification and analysis of hepatitis C virus NS3 helicase inhibitors using nucleic acid binding assays |
| Q34789828 | Identification of Novel IGF1R Kinase Inhibitors by Molecular Modeling and High-Throughput Screening |
| Q33828282 | Inhibition of IGF-1 receptor kinase blocks the differentiation into cardiomyocyte-like cells of BMSCs induced by IGF-1 |
| Q33925323 | Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach |
| Q36583516 | Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer |
| Q33911127 | Insulin and IGF receptor signalling in neural-stem-cell homeostasis. |
| Q38410339 | Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes. |
| Q38361469 | Insulin-like growth factor-1 increases skeletal muscle dihydropyridine receptor alpha 1S transcriptional activity by acting on the cAMP-response element-binding protein element of the promoter region |
| Q45298969 | Insulin-like growth factor-1 inhibits adult supraoptic neurons via complementary modulation of mechanoreceptors and glycine receptors. |
| Q41113979 | Insulin-like growth factor-1 receptor regulates repair of ultraviolet B-induced DNA damage in human keratinocytes in vivo. |
| Q37596299 | Insulin-like growth factor-II (IGF-II) and IGF-II analogs with enhanced insulin receptor-a binding affinity promote neural stem cell expansion |
| Q37537075 | Measuring and interpreting the selectivity of protein kinase inhibitors |
| Q41694546 | Nigella sativa Relieves the Altered Insulin Receptor Signaling in Streptozotocin-Induced Diabetic Rats Fed with a High-Fat Diet. |
| Q39939584 | Nordihydroguaiaretic acid inhibits an activated fibroblast growth factor receptor 3 mutant and blocks downstream signaling in multiple myeloma cells |
| Q39850815 | Novel insulin-like growth factor-methotrexate covalent conjugate inhibits tumor growth in vivo at lower dosage than methotrexate alone |
| Q48322740 | Paul Ehrlich's magic bullet concept: 100 years of progress |
| Q44578387 | Preservation of motor neuron Ca2+ channel sensitivity to insulin-like growth factor-1 in brain motor cortex from senescent rat. |
| Q94545894 | Proteomic analysis of combined IGF1 receptor targeted therapy and chemotherapy identifies signatures associated with survival in breast cancer patients |
| Q38495042 | Re-positioning protein-kinase inhibitors against schistosomiasis |
| Q37113552 | Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma. |
| Q54246015 | Readout technologies for highly miniaturized kinase assays applicable to high-throughput screening in a 1536-well format. |
| Q36163571 | Role of insulin-like growth factor 1 receptor signalling in cancer |
| Q34992505 | Small molecule substrate phosphorylation site inhibitors of protein kinases: approaches and challenges. |
| Q34669625 | Structural biology in drug design: selective protein kinase inhibitors |
| Q39640546 | Syndecan-1 couples the insulin-like growth factor-1 receptor to inside-out integrin activation |
| Q40521524 | The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway |
| Q46890855 | The insulin-like growth factor-1 receptor inhibitor PPP produces only very limited resistance in tumor cells exposed to long-term selection |
| Q56995355 | The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion |
| Q44328420 | The pp60c-Src inhibitor PP1 is non-competitive against ATP. |
| Q35964712 | The therapeutic potential of agents targeting the type I insulin-like growth factor receptor |
| Q36185627 | Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling |
| Q40659303 | Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. |
| Q35045444 | Tyrosine kinases as targets for cancer therapy |
| Q36538579 | Virtual screening of specific insulin-like growth factor 1 receptor (IGF1R) inhibitors from the National Cancer Institute (NCI) molecular database |
| Q35005700 | δ-Opioid receptors stimulate GLUT1-mediated glucose uptake through Src- and IGF-1 receptor-dependent activation of PI3-kinase signalling in CHO cells |
Search more.